Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

MODERNA EXPECTS TO REAP $18.4 BILLION FROM VACCINE SALES

Ten-year-old Moderna Therapeutics will collect $18.4 billion this year from COVID vaccine sales, more than half as much as the $11.2 billion analysts have forecast and more than the $15 billion Pfizer expects to see.
Revenues for 2021 could rise higher, Moderna said, as governments ramp up orders for vaccines and the Covax vaccine program for developing nations progresses.
Moderna’s share price closed at $154.81 on 26 February, up 8 percent.
“We previously believed that mRNA” – the vaccine design the company used – “would lead to approved medicines,” CEO Stephane Bancel said in comments quoted by the Financial Times. “We were limited in our ambitions by the need for regular capital raises and by keeping several years of cash to manage financial risk.”
Moderna’s successful vaccine has eased those limitations.
“Many governments have been telling us they would like more of our vaccine, based on its high efficacy,” he said.
Moderna also has developed a booster vaccine for the South African variant. The new serum will be tested in trials at the U.S. National Institutes of Health.
The company reported $571 million in fourth-quarter revenue but still lost $272 million for the year, compared to $123 million in red ink in 2019.

Comments are closed.